It has also been shown that type I IFN treatment can enhance the cytotoxic effect of MEK inhibition in melanoma cell lines with low activity of IFN pathway 39 and since MX2 can induce IFN response profile affecting multiple genes, it is likely that these additional downstream factors are mediating this sensitization. The gene discussed is MX2; the disease is melanoma.